DOJ Investigates Andreessen Horowitz: What This Means for Venture Capital Governance and Board Conflicts
Table of Contents
You might want to know
1. Could common board representation across portfolio companies become an antitrust liability for venture capital firms?
2. When startups expand into adjacent markets, how should investors balance support with potential conflicts?
Main Topic
The recent reports that the U.S. Department of Justice is investigating Andreessen Horowitz (a16z) over overlapping board representation bring renewed attention to a longstanding tension in venture capital: how firms support multiple portfolio companies while avoiding conflicts that could draw regulatory scrutiny. At the center of the inquiry are two a16z partners who sit on the boards of companies that now operate in increasingly adjacent, and in some respects competing, markets. One partner serves on the board of Databricks while another sits on the board of Fivetran. That arrangement, benign on its face when investments were first made, has become more complicated as both companies have broadened their product scopes and target customers.
For decades, venture capitalists have commonly taken board seats or observer roles to help guide startups through product development, hiring, fundraising, and strategic partnerships. Those roles let investors influence company direction, protect their capital, and surface synergies across a portfolio. Yet when two portfolio companies move into overlapping spaces, the same governance links that once seemed helpful can be reframed as potential channels for anticompetitive coordination or information exchange. The DOJ's reported interest in using an older antitrust statute underlines that regulators may view certain board relationships as more than governance tools; they may see them as structures that could facilitate collusion or reduce competitive intensity.
Several elements make this issue complex. First, startups evolve rapidly. Two companies that were complementary at the time of investment can become rivals as they scale and expand product lines. Venture firms rarely have complete foresight into how markets will develop, and portfolio strategies naturally adapt. Second, the responsibilities and duties of board members are fiduciary to the company on whose board they sit. A partner who serves on multiple boards must navigate confidentiality, prioritization of fiduciary duties, and the optics of divided loyalties. Third, the legal and regulatory environment for antitrust enforcement has been changing; agencies and legislators are more attuned to concentration and collusion risks in technology and platform markets, and they may be willing to apply less-used statutes to modern VC practices.
From a practical governance standpoint, venture firms and founders can adopt several approaches to mitigate both actual conflicts and regulatory concerns. One path is to limit board representation: firms might reduce the number of partners who accept board seats, favor observer roles with more constrained information rights, or explicitly prohibit serving on boards of companies operating in the same category. Another option is to adopt strong information firewalls and documented procedures for handling confidential information, including strict recusal policies for decisions that could affect competing portfolio companies. Clear, documented decision-making can help demonstrate that connections between companies are not being used to coordinate pricing, market allocation, or other anticompetitive behavior.
There are trade-offs. Holding fewer board seats may reduce an investor's ability to steer strategy or protect downside risk. It could also weaken the value-add that many founders expect from well-networked firms. Conversely, tighter controls could preserve the firm's reputation and reduce legal exposure but at the cost of hands-on involvement. Some firms may elect to bifurcate teams—separating partners who lead certain sector investments from those who take board roles—to create natural distance between potentially overlapping investments.
Regulatory action, if it proceeds beyond inquiry, could set important precedents. Antitrust enforcement that targets VC board overlap would likely prompt industry-wide changes in governance norms, term sheet language, and portfolio construction. Documented limitations on multiple board seats or standardized conflict-of-interest policies might become commonplace. Investors could also see greater use of contractual safeguards, such as non-disclosure and no-sharing clauses between portfolio companies, formalized at the time of investment. On the other hand, overly broad restrictions risk stifling beneficial collaboration, slowing the rate at which startups access operational expertise and capital guidance—a dynamic that has historically accelerated innovation.
It's also important to consider intent and effects. Antitrust authorities generally distinguish between competitive effects and benign collaboration. If shared board members are simply providing governance and there is no evidence of coordinated pricing, market division, or information exchange that harms competition, regulators may determine enforcement is unnecessary. However, when the potential for anti-competitive effects increases—particularly in concentrated markets with high barriers to entry—regulators may take a closer look. Using older statutes shows the DOJ has tools it can repurpose to fit contemporary issues in venture financing and governance.
Finally, transparency and proactive compliance will matter. Firms facing scrutiny can protect themselves by maintaining clear records of board interactions, decisions, and steps taken to avoid conflicts. Open dialogue with portfolio companies, explicit consent where overlap is foreseeable, and advice from antitrust counsel can help mitigate risk. The arrival of this legal debate into public view should prompt boards, investors, and founders to reassess how they structure relationships as product roadmaps and markets shift.
In short, the a16z situation is not only about two specific companies or partners. It signals a broader question for the venture ecosystem: how to reconcile active governance and cross-portfolio involvement with a regulatory environment that is increasingly sensitive to potential anti-competitive dynamics. The answers will shape how firms invest, how they govern, and how startups expect to be supported by their backers in the years ahead. The stakes include both legal exposure and the practical effectiveness of investor involvement, and the balance struck will influence industry norms and investor behavior.
Key Insights Table
| Aspect | Description |
|---|---|
| Issue | DOJ scrutiny of overlapping board representation at a16z amid growing competition between portfolio companies. |
| Legal angle | Use of an older antitrust statute to evaluate whether governance arrangements could enable anti-competitive coordination. |
| Governance tension | Balancing active investor support with fiduciary duties and confidentiality when portfolio boundaries shift. |
| Mitigation strategies | Limit board seats, adopt observers, implement firewalls, recusal policies, and clearer documentation. |
| Industry impact | Potential shift in VC norms, term sheets, and compliance practices if enforcement becomes common. |
Afterwards...
Looking ahead, the outcome of this investigation could prompt venture firms to formalize how they manage board roles and conflicts. Expect more standardized governance clauses, increased use of observers instead of full board seats, and more routine involvement of antitrust counsel in deal structuring. Founders should be prepared to ask investors about their conflict policies, and investors will need to weigh how hands-on they want to be against the legal and reputational costs of overlapping influence. Ultimately, the industry will need solutions that preserve the benefits of active investor involvement while minimizing the risk of regulatory intervention and protecting competitive market dynamics.
